Experimental Hematology
Volume 30, Issue 10 , Pages 1178-1184 , October 2002

Isolation and expansion of human cytomegalovirus- specific cytotoxic T lymphocytes using interferon-γ secretion assay

  • Alfred Lennart Bissinger

      Affiliations

    • Medizinische Klinik II, Eberhard-Karls-Universität Tübingen, Tübingen, Germany
    • Medizinische Virologie, Eberhard-Karls-Universität Tübingen, Tübingen, Germany
    • The first two authors contributed equally to this work.
    • ,
  • Georg Rauser

      Affiliations

    • Medizinische Klinik II, Eberhard-Karls-Universität Tübingen, Tübingen, Germany
    • The first two authors contributed equally to this work.
    • ,
  • Holger Hebart

      Affiliations

    • Medizinische Klinik II, Eberhard-Karls-Universität Tübingen, Tübingen, Germany
    • ,
  • Friederike Frank

      Affiliations

    • Medizinische Klinik II, Eberhard-Karls-Universität Tübingen, Tübingen, Germany
    • ,
  • Gerhard Jahn

      Affiliations

    • Medizinische Virologie, Eberhard-Karls-Universität Tübingen, Tübingen, Germany
    • ,
  • Hermann Einsele

      Affiliations

    • Corresponding Author InformationOffprint requests to: Hermann Einsele, M.D., Medizinische Klinik II, Otfried-Müller-Straβe 10, D-72076 Tübingen, Germany
    • Medizinische Klinik II, Eberhard-Karls-Universität Tübingen, Tübingen, Germany

Received 18 March 2002 ,Revised 31 May 2002 ,Accepted 11 June 2002.

References 

  1. Boeckh M, Bowden RA, Gooley T, Myerson D, Corey L. Successful modification of a pp65 antigenemia-based early treatment strategy for prevention of cytomegalovirus disease in allogeneic marrow transplant recipients. Blood. 1999;93:1781
  2. Einsele H, Ehninger G, Hebart H, et al.  Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood. 1995;86:2815
  3. Ljungman P, Engelhard D, Link H, et al.  Treatment of interstitial pneumonitis due to cytomegalovirus with ganciclovir and intravenous immune globulin (experience of European Bone Marrow Transplant Group). Clin Infect Dis. 1992;14:831
  4. Einsele H, Hebart H, Kauffmann SC, et al.  Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection. Bone Marrow Transplant. 2000;25:757
  5. Eckle T, Prix L, Jahn G, et al.  Drug-resistant human cytomegalovirus infection in children after allogeneic stem cell transplantation may have different clinical outcomes. Blood. 2000;96:3286
  6. Krause H, Hebart H, Jahn G, Muller CA, Einsele H. Screening for CMV-specific T cell proliferation to identify patients at risk of developing late onset CMV disease. Bone Marrow Transplant. 1997;19:1111
  7. Ljungman P, Lonnqvist B, Wahren B, Ringden O, Gahrton G. Lymphocyte responses after cytomegalovirus infection in bone marrow transplant recipients—a one-year follow-up. Transplantation. 1985;40:515
  8. Reusser P, Riddell SR, Meyers JD, Greenberg PD. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation (pattern of recovery and correlation with cytomegalovirus infection and disease). Blood. 1991;78:1373
  9. Walter EA, Greenberg PD, Gilbert MJ, et al.  Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med. 1995;333:1038
  10. Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science. 1992;257:238
  11. Einsele H, Roosnek E, Rufer N, et al.  Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood. 2002;99:3916
  12. Szmania S, Galloway A, Bruorton M, et al.  Isolation and expansion of cytomegalovirus-specific cytotoxic T lymphocytes to clinical scale from a single blood draw using dendritic cells and HLA-tetramers. Blood. 2001;98:505
  13. Kleihauer A, Grigoleit U, Hebart H, et al.  Ex vivo generation of human cytomegalovirus-specific cytotoxic T cells by peptide-pulsed dendritic cells. Br J Haematol. 2001;113:231
  14. Vannucchi AM, Glinz S, Bosi A, Caporale R, Rossi-Ferrini P. Selective ex vivo expansion of cytomegalovirus-specific CD4+ and CD8+ T lymphocytes using dendritic cells pulsed with a human leucocyte antigen A*0201-restricted peptide. Br J Haematol. 2001;113:479
  15. Peggs K, Verfuerth S, Mackinnon S. Induction of cytomegalovirus (CMV)-specific T-cell responses using dendritic cells pulsed with CMV antigen (a novel culture system free of live CMV virions). Blood. 2001;97:994
  16. Diamond DJ, York J, Sun JY, Wright CL, Forman SJ. Development of a candidate HLA A*0201 restricted peptide-based vaccine against human cytomegalovirus infection. Blood. 1997;90:1751
  17. Solache A, Morgan CL, Dodi AI, et al.  Identification of three HLA-A*0201-restricted cytotoxic T cell epitopes in the cytomegalovirus protein pp65 that are conserved between eight strains of the virus. J Immunol. 1999;163:5512
  18. Wills MR, Carmichael AJ, Mynard K, et al.  The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65 (frequency, specificity, and T-cell receptor usage of pp65-specific CTL). J Virol. 1996;70:7569
  19. Brosterhus H, Brings S, Leyendeckers H, et al.  Enrichment and detection of live antigen-specific CD4(+) and CD8(+) T cells based on cytokine secretion. Eur J Immunol. 1999;29:4053
  20. Becker C, Pohla H, Frankenberger B, et al.  Adoptive tumor therapy with T lymphocytes enriched through an IFN-γ capture assay. Nat Med. 2001;7:1159
  21. Kern F, Surel IP, Brock C, et al.  T-cell epitope mapping by flow cytometry. Nat Med. 1998;4:975

PII: S0301-472X(02)00897-4

Experimental Hematology
Volume 30, Issue 10 , Pages 1178-1184 , October 2002

Article Tools

* Image Usage & Resolution